Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179920 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma
A Phase 2 study of Retinoblastoma and Retinal Neoplasms, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00179920 is a Phase 2 study of Retinoblastoma and Retinal Neoplasms that has completed, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 30 participants, below the 591-participant average among 15 other Retinoblastoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00179920, a Phase 2 study of Retinoblastoma and Retinal Neoplasms, has completed, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Retinoblastoma is an unusual cancer of early childhood involving tumor is both eyes or, in certain circumstances, one eye only. This condition is the result of an abnormal gene which makes both retinas (the back of the eye) vulnerable to develop multiple tumors. Growths in the eye impair vision temporarily or permanently. These tumors are malignant, which means that they can grow within the eye, spread outside of the eye, and be fatal if untreated. Standard therapy for bilateral retinoblastoma includes removal of one eye if vision cannot be save and radiation treatment of either eye in which vision might be saved. Radiation controls tumor growth in the majority of cases. Another standard method is cryotherapy (freezing a tumor to kill it). Chemotherapy (medicines used to kill tumor cells) has been used in the past for tumor in or outside the eye, but is not standard. Hyperthermia, increasing the temperature of a tumor to kill it, is widely performed, and can be done to a retinoblastoma tumor by a laser; this method is not standard. The problem with removal of an eye is that any hope of vision is lost. The problems with radiation include incomplete control of tumor, injury to the eye or surrounding tissue with decreased growth, and that (due to the abnormal retinoblastoma gene) children are very susceptible to develop other tumors, especially in the tissue which was given radiation. The doctors at Children's Memorial Hospital are using a newer form of treatment, including laser hyperthermia, chemotherapy and cryotherapy to decrease retinoblastoma tumors. Some may be controlled indefinitely, reducing the number of eyes that need radiation or removal. OBJECTIVES 1. To find out how well chemotherapy plus cryotherapy and laser hyperthermia work on retinoblastoma tumors. 2. To find out whether vision can be saved and tumors controlled without radiation or removal of the eye.
Conditions Studied
Interventions
- DRUG Carboplatin
- PROCEDURE Cryotherapy
- DRUG VP-16
- PROCEDURE Local Surgery
- PROCEDURE Laser hyperthermia
Study Locations (1)
Illinois
- Children's Memorial Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1996-04 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00179920
The ClinicalTrials.gov registry entry for NCT00179920 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 591-participant average among 15 other Retinoblastoma trials with a reported enrollment target (95% lower). The listed sponsor is Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Retinoblastoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT00179920 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00179920 about?
NCT00179920 is a clinical study titled "Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma". Retinoblastoma is an unusual cancer of early childhood involving tumor is both eyes or, in certain circumstances, one eye only. This condition is the result of an abnormal gene which makes both retinas (the back of the eye) vulnerable to develop multiple tumors. Growths in the eye impair vision temp...
What is the current status of trial NCT00179920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1996-04. Estimated completion is 2006-09.
What conditions does trial NCT00179920 study?
This clinical trial studies the following conditions: Retinoblastoma, Retinal Neoplasms.
What interventions are being tested in trial NCT00179920?
The interventions under investigation include: Carboplatin (DRUG), Cryotherapy (PROCEDURE), VP-16 (DRUG), Local Surgery (PROCEDURE), Laser hyperthermia (PROCEDURE).
Who is sponsoring clinical trial NCT00179920?
This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00179920 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinoblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Retinoblastoma Phase II Expanded Access Clinical Trial
RECRUITING · Phase 2
-
Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
ACTIVE NOT RECRUITING · Phase 2
-
Chemotherapy in Treating Patients With Retinoblastoma
COMPLETED · Phase 2
-
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
COMPLETED · Phase 2
-
RB Liquid Biopsy Biorepository
RECRUITING
-
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.